Business Wire

Cymulate Reveals Next-level AI Automation for Threat Exposure Validation

18.2.2025 15:00:00 CET | Business Wire | Press release

Share

The company introduces first-of-a-kind automated remediation to eliminate threat exposure, optimize controls and mitigate validated security gaps

Cymulate, the leader in threat exposure validation, today announced the next evolution of the company’s flagship security validation platform. As a pioneer and market leader for breach and attack simulation (BAS) and automated red teaming, Cymulate continues to innovate with automation and artificial intelligence (AI) to deliver the most advanced and easiest-to-use threat exposure validation on the market. At a time when attackers are deploying more advanced tactics than ever, the Cymulate Exposure Validation Platform leverages the power of AI to give every blue and red teamer the automation and accessibility to validate and remediate threat exposure and optimize security.

Exposure validation helps organizations go further than traditional solutions like BAS and automated penetration testing. By embracing the CTEM strategy, security teams can validate their exposure according to their defined threat scope, prioritize contextually according to their specific security strategy, and mobilize while continuously and automatically remediating gaps.

“Security leaders recognize that they need to rapidly address the most exploitable threats in a continuous fashion. Cymulate is bringing first-to-market innovation and automation in our Exposure Validation Platform so security teams can fix their biggest gaps and improve defensive posture before it’s too late,” said Avihai Ben-Yossef, Co-founder and CTO, Cymulate. “We’ve made technologies like attack simulation and automated red teaming easy to implement with actionable findings. Customers are seeing results that reduce noise, clarify decision making and increase the ROI of cyber defense investments.”

The Cymulate Exposure Validation Platform allows security teams to validate their controls alongside potential threats and response tactics, determining which threats are most risky and generating a remediation strategy that prioritizes those exposures first and automates control optimization. Innovative new features include:

  • An AI-powered agent that guides blue teamers and red teamers to create the most impactful validation for their focus – from best practices to industry-specific threats to detailed attack chains from the latest threat intel
  • Streamlined attack simulations that create easier assessments across the MITRE ATT&CK kill chain for all environments, including the most comprehensive library of cloud and Kubernetes attack scenarios
  • A new attack scenario workbench designed to create comprehensive validation assessments from a library of more than one million attack actions or custom scenarios
  • Modular and dynamic assessments that help test for new threats

A key aspect of the Cymulate Exposure Validation Platform is an elevation in the outcome that allows actionable and vendor-specific remediation. Security teams can use their existing stack to manually add optimization rules. Cymulate then automatically pushes these rules to the security controls and automates the entire remediation process.

“The Cymulate Exposure Validation Platform makes advanced security testing fast and easy. When it comes to building custom attack chains, it’s all right in front of you in one place. You can access the full Cymulate library or build your own attack actions,” said Mike Humbert, Cybersecurity Engineer at Cymulate customer Darling Ingredients Inc. “As you start to click and filter, you have the ability to refine what you’re testing, schedule the assessment and drill down to results.”

To learn more about the Cymulate Exposure Validation Platform, visit www.cymulate.com.

About Cymulate

Cymulate, the leader in security and exposure validation, provides the single source of truth for threat exposure and the actions required to close security gaps before attackers can exploit them. More than 1,000 customers worldwide rely on the Cymulate platform to baseline their security posture and strengthen cyber resilience with continuous discovery, validation, prioritization, and guided remediation of security weaknesses. Cymulate automates advanced offensive security testing to validate controls, threats, and attack paths. As an open platform, Cymulate integrates with existing security and IT infrastructure and drives the workflows of the exposure management process. For more information, visit www.cymulate.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218739287/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye